A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China - CNBC
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China CNBC Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer statnews.com Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means Endpoints News ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% Fierce Pharma Lung Cancer Patients on Drug From China’s Akeso Lived Longer Bloomberg.com
YesNo saves this item as an on-site live signal so search users can understand how it connects to prediction markets and incubation topics.
If later reporting creates a clear deadline, official source, or verifiable outcome, the public event can become a tradable Yes/No question.
This item has a verifiable event angle that can be monitored for a Yes/No prediction market.